Skip to main content

Fiscal Wizard · Single-issue tearsheet

INDV / Jun 21, 2026 Run #7413

INDV

Indivior Pharmaceuticals, Inc.

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Composite verdict

B 73.2 / 100
Bullish setup · Trend Following 13 drivers · 3 gates blocking
  • Rate of Change
  • Coppock Curve
  • Vortex Signal
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 4th of 85 in Drug Manufacturers - Specialty & Generic

rescore-sweep
Technical synthesisRegime: range
Bull 100%Evidence: High · 22 signals0% Bear
Momentum Bullish 96Mean-reversion Neutral 54

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from
Asset value $-0.83Earnings power value $20.84Price $38.30

Priced above its no-growth earnings power value ($20.84/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

46.4 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
OCF to Net Income 0
Return on Capital Employed 100
Free Cash Flow Yield 0
Asset Turnover 84
Cash Conversion 0

Technicals Bullish

100.0 / 100

Bullish setup leads (Rate of Change, Coppock Curve, Vortex Signal); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 93
Vortex Signal 85
Coppock Curve 85

Risk Gates

3 blocking 7 caution

3 guards active, 19 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for INDV.